APM:NSD-Aptorum Group Limited (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.55

Change

-0.05 (-1.92)%

Market Cap

USD 0.09B

Volume

0.20M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Company Website : http://www.aptorumgroup.com

Address : 17 Hanover Square, London, United Kingdom, W1S 1BN

Employees : 36

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.16

52 Week High : 4.98

Short Ratio : 0.91

52 Week Low : 1.16

Shorted Shares : 186,358

200 Day Moving Average : 2.85

Shorted Shares Previous Month : 216,620

50 Day Moving Average : 3.08

Shares Held By Insiders : 264.27%

Short Percentage : 1.00%

Shares Held by Institutions : 1.5%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-0.16 (-0.10%)

 USD64.10B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+3.97 (+1.83%)

 USD56.20B 21.10 15.27
REGN Regeneron Pharmaceuticals, Inc

+13.48 (+2.80%)

 USD51.55B 15.77 12.24
ALXN Alexion Pharmaceuticals, Inc

+2.25 (+1.45%)

 USD34.14B 57.09 33.71
BNTX BioNTech SE

+8.12 (+6.12%)

 USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.16 (+2.38%)

 USD27.77B N/A N/A
SGEN Seagen Inc

+5.44 (+3.77%)

 USD26.14B 42.79 34.88
RPRX Royalty Pharma plc

-0.47 (-1.12%)

 USD25.57B 22.60 15.33
GMAB Genmab A/S

+0.31 (+0.89%)

 USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing APM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.24% 57% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.24% 57% F 41% F
Trailing 12 Months  
Capital Gain -22.02% 20% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.02% 20% F 6% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -35.68% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.68% 4% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 41.30% 75% C 41% F
Risk Adjusted Return -86.39% 4% F 2% F
Market Capitalization 0.09B 15% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 86.67 11% F 14% F
Price/Book Ratio 4.94 48% F 35% F
Price / Cash Flow Ratio -6.64 44% F 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -84.08% 33% F 14% F
Return on Invested Capital -55.22% 45% F 15% F
Return on Assets -47.55% 17% F 6% F
Debt to Equity Ratio 38.69% 30% F 46% F
Technical Ratios  
Short Ratio 0.91 77% C+ 71% C-
Short Percent 2.19% 85% B 63% D
Beta -0.16 96% A 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector